


Azaribine

Cat. No.:	HY-B1537
CAS No.:	2169-64-4
Molecular Formula:	C ₁₄ H ₁₇ N ₃ O ₉
Molecular Weight:	371.3
Target:	Influenza Virus; Virus Protease
Pathway:	Anti-infection
Storage:	-20°C, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



BIOLOGICAL ACTIVITY

Description	<p>Azaribine (2',3',5'-Tri-O-acetyl-6-azauridine) is a potent orotidine monophosphate decarboxylase (OMPD) inhibitor. Azaribine is an antiviral inhibitor of several RNA viruses and inhibits viral genome replication and gene transcription. Azaribine shows broad-spectrum antiviral activity (EC₅₀=3.80 nM-1.73 μM against influenza A and B viruses; EC₅₀=1.62 μM against ZIKV Paraiba). Azaribine, a triacetate salt of Azauridine, has the potential for psoriasis research^{[1][2]}.</p>								
In Vitro	<p>Azaribine (2',3',5'-Tri-O-acetyl-6-azauridine; 0-2 μM; 48 h) has cytotoxicity on MDCK cells (MTT: CC₅₀=19.66 μM)^[1]. Azaribine shows a potent inhibitory effect on BIRFLU multiplication (MDCK cells: EC₅₀=0.29 μM; A549 cells: EC₅₀=0.55 μM)^[1]. Azaribine shows against seasonal H1N1 and H3N2 IAVs and IBV during posttreatment in MDCK cells with EC₅₀ of 0.60 μM, 0.77 μM, 0.80 μM^[1]. Azaribine is against NC H1N1 during posttreatment in 16HBE cells (EC₅₀=1.58 μM)^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Cytotoxicity Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>MDCK cells</td> </tr> <tr> <td>Concentration:</td> <td>0-2 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 h</td> </tr> <tr> <td>Result:</td> <td>Had cytotoxicity on MDCK cells (CC₅₀=19.66 μM).</td> </tr> </table>	Cell Line:	MDCK cells	Concentration:	0-2 μM	Incubation Time:	48 h	Result:	Had cytotoxicity on MDCK cells (CC ₅₀ =19.66 μM).
Cell Line:	MDCK cells								
Concentration:	0-2 μM								
Incubation Time:	48 h								
Result:	Had cytotoxicity on MDCK cells (CC ₅₀ =19.66 μM).								

REFERENCES

[1]. Jun-Gyu Park, et al. Identification and Characterization of Novel Compounds with Broad-Spectrum Antiviral Activity against Influenza A and B Viruses. *J Virol*. 2020 Mar 17;94(7):e02149-19.

[2]. Desarey Morales Vasquez, et al. Identification of Inhibitors of ZIKV Replication. *Viruses*. 2020 Sep 18;12(9):1041.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA